Which inhaled corticosteroid has the highest topical potency and the lowest systemic bioavailability due to extensive first-pass hepatic metabolism?

Explanation

## Inhaled Corticosteroid Potency and Bioavailability **Key Point:** Fluticasone propionate (FP) is the most potent inhaled corticosteroid with the lowest systemic bioavailability (~1%), making it the safest option for long-term use, especially in children. ### Mechanism of Low Systemic Bioavailability Fluticasone propionate achieves minimal systemic exposure through: 1. **High lipophilicity** — deposits extensively in lung tissue, creating a local depot effect 2. **Rapid hepatic metabolism** — undergoes extensive first-pass metabolism via CYP3A4 to inactive metabolites 3. **Poor oral absorption** — swallowed portion is rapidly metabolized in the liver 4. **High protein binding** — binds extensively to plasma proteins, reducing free drug concentration ### Comparison of Inhaled Corticosteroids | ICS | Topical Potency | Systemic Bioavailability | First-Pass Metabolism | Clinical Use | | --- | --- | --- | --- | --- | | **Fluticasone propionate** | Highest | ~1% | Extensive (CYP3A4) | Preferred for maintenance, children | | **Budesonide** | High | ~10% | Moderate | Second-line, pregnancy-safe | | **Beclomethasone dipropionate** | Moderate | ~20% | Moderate | Older agent, less preferred | | **Triamcinolone acetonide** | Moderate | ~25% | Minimal | Higher systemic risk | **High-Yield:** Fluticasone propionate is the **gold standard** ICS for long-term asthma control in both adults and children due to superior topical selectivity and minimal systemic effects. **Clinical Pearl:** Even though fluticasone has the highest potency, its low systemic bioavailability means it causes fewer HPA-axis suppression and growth retardation effects compared to older agents like triamcinolone. **Mnemonic:** **FP = First-Pass Friendly** — Fluticasone Propionate undergoes extensive first-pass metabolism, keeping systemic exposure minimal.